Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma

17 Jun 2009

Abstract excerpt

The proteasome inhibitor bortezomib (Velcade) is currently approved as second-line treatment of multiple myeloma (MM). MM-related bone disease is one of the most debilitating complications of MM. Besides supportive care with biphosphonates, which have proven efficacy in reducing and delaying skeletal-related events, there is no specific treatment of lytic bone lesions. The present study investigated the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19531653
DOI: 10.1158/0008-5472.can-08-4472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of MyelomaPMID 19531653Read ↗

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaSemantic proximity Read ↗

Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.Semantic proximity Read ↗

Osteoblast suppression in multiple myeloma bone diseaseSemantic proximity Read ↗

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cellsSemantic proximity Read ↗

Epigenetic‐Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone DiseaseSemantic proximity Read ↗

Romosozumab Safely Restores Bone Mass in Multiple Myeloma via Osteoblast Reprogramming: A Phase IIa StudySemantic proximity Read ↗

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.Semantic proximity Read ↗

Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretionSemantic proximity Read ↗

Marked Osteoblastopenia and Reduced Bone Formation in a Model of Multiple Myeloma Bone Disease in Severe Combined Immunodeficiency MiceSemantic proximity Read ↗

Novel Proteasome Inhibitors to Overcome Bortezomib ResistanceSemantic proximity Read ↗

Discovery of Cytotoxic Truncated Vitamin D Derivatives Against Both Bortezomib‐Sensitive and Resistant Multiple Myeloma PhenotypesSemantic proximity Read ↗

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.